Cutter Capital Management LP Purchases Shares of 584,883 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Cutter Capital Management LP bought a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 584,883 shares of the company's stock, valued at approximately $12,891,000. Teva Pharmaceutical Industries accounts for about 5.3% of Cutter Capital Management LP's investment portfolio, making the stock its 9th biggest holding. Cutter Capital Management LP owned approximately 0.05% of Teva Pharmaceutical Industries as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Robeco Institutional Asset Management B.V. grew its position in Teva Pharmaceutical Industries by 7.2% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock worth $10,983,000 after buying an additional 33,277 shares in the last quarter. Pinnbrook Capital Management LP acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $4,966,000. Asset Management One Co. Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 14.6% in the fourth quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock valued at $10,414,000 after buying an additional 58,413 shares during the period. CWA Asset Management Group LLC bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at $3,340,000. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Teva Pharmaceutical Industries by 2,018.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company's stock valued at $23,368,000 after buying an additional 1,045,305 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on TEVA shares. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. UBS Group reduced their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. StockNews.com raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, April 23rd. Finally, Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $23.71.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock traded down $1.13 during midday trading on Friday, hitting $16.94. 19,072,081 shares of the company's stock were exchanged, compared to its average volume of 10,028,635. The stock has a 50-day moving average price of $15.18 and a two-hundred day moving average price of $17.45. The company has a market cap of $19.21 billion, a P/E ratio of -11.68, a PEG ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a 52-week low of $12.47 and a 52-week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. The firm had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The company's revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.48 earnings per share. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.